Studies on histone deacetylase inhibitors (HDACIs) showed that these agents could cause an upregulation of glioma cell MKP1; thus, MKP1 is a promising treatment strategy targeting resistant GSCs (82). The gene discussed is DUSP1; the disease is glioma.